

How a single non-conventional amino acid can modify the effectiveness of amphibian antimicrobial peptides



Maria Rosa Loffredo¹, Bruno Casciaro¹, Giacomo Cappella¹, Rosa Bellavita², Diego Brancaccio², Floriana Cappiello¹, Francesco Merlino², Paolo Grieco², Lorenzo Stella³, Alfonso Carotenuto², Maria Luisa Mangoni¹



¹Department of Biochemical Sciences, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, 00185 Rome, Italy; ²Department of Pharmacy, University of Naples "Federico II", Via D. Montesano 49, 80131 Naples, Italy. ³ Department of Chemical Science and Technologies, University of Rome Tor Vergata, 00133 Rome, Italy.

Background

Esculentin(1-21) [Esc(1-21)] is a short-sized peptide antimicrobial (AMP) cationic corresponding to the N-terminal region of the frog-skin AMP esculentin-1a. It is endowed with a fast rate of killing activity, especially against Gram-negative bacteria, by a membrane perturbing mechanism of action.



>Short size

> A large spectrum of activity (Gram⁻, Gram⁺, fungi) >A potent activity against planktonic and biofilm forms of *Pseudomonas aeruginosa* (Gram⁻).



Rana esculenta https://doi.org/10.17952/37EPS.2024.P2086

```
Antimicrobial activity of Esc(1-21) against reference
strains and clinical isolates of P. aeruginosa
```



RESULTS

Design and Synthesis of Glycine-Replaced Derivative of Esc(1-21)

Antimicrobial activity of [Aib⁸]

Fig. 1 Primary structure of Esc(1-21) and its derivative With the aim to increase the biological activity of Esc(1-21) GIFSKLAGKKIKNLLISGLKG-NH₂ against Gram-positive bacteria we **Esc(1-21)** explored the effect of the replacement of Glycine amino acid residue in **position 8** with a non-GIFSKLAAibKKIKNLLISGLKG-NH₂ coded amino acid, (Fig. 1) [Aib⁸] α-aminoisobutyric acid, [Aib⁸]. Residue variation is highlighted in red. The last glycine is amidated on the C-terminus.

Effect of [*Aib*⁸] *on Cell Viability*



[Aib⁸] did not induce any significant cytotoxic effect on HaCaT cells up to a concentration of 25 µM after 24h of treatment on metabolically active cells (Fig. 2).

Fig. 2 Effect of [Aib⁸] on the viability of HaCaT cells was evaluated using the MTT assay after 24 h treatment. All data are expressed as percentage with respect to the untreated control cells.

Strain	ΜΙC (μΜ)	
Gram-Negative	Esc (1-21)	[Aib ⁸]
E. coli ATCC 25922	1.56	0.78
A. baumannii ATCC 19606	1.56	0.78
P. aeruginosa ATCC 25853	3.12	3.12
Gram-Positive		
S. epidermidis ATCC 12228	3.12	0.78
S. aureus ATCC 25923	>100	12.5
S. aureus MDR #1	>100	12.5
S. aureus MDR #2	100	12.5
S. aureus MDR #3	100	12.5
S. aureus MDR #4	>100	6.25
Tab. 1 Antimicrobial activity of Esc-pept	tides	

The parent peptide Esc (1-21) did not show any antibacterial effect against S. aureus. On the contrary, [Aib⁸] showed strong activity against the Gram-positive S. epidermidis strain, and it was also effective against the Gram-positive S. aureus ATCC 25923 and multi-drug resistant strains (Tab. 1).

NMR analysis in the presence of POPG/POCL bicelles

Antibiofilm activity of [Aib⁸]



Fig. 3. Antibiofilm activity of [Aib⁸] against S. aureus ATCC 25923 and S. aureus #4, after 2 h of treatment. Biofilm viability was evaluated by MTT assay and expressed as percentage compared to that of untreated samples (bacterial biofilm not treated with the peptide, 100% viabilitv)

Esc (1-21) was able to reduce ~90% of biofilm viability at 100 μ M against the reference strain of S. aureus ATCC 25923. On the contrary, [Aib⁸] was able to reduce more than 90% biofilm viability of both reference and clinical isolates at concentrations of 25 μ M, which are only 2- or 4fold higher than the corresponding MIC against the two strains (Fig. 3).

Stability of [Aib⁸] in Serum To investigate the stability of the Circular Dichroism Analysis in POPG/POCL LUVs

[Aib⁸]

fluids,

peptide

monitored

24h

in

presence of 50%

serum (Fig 4).

In

of

at

the

bovine

promising

derivate

intact

within

37°C

incubation

was

biological

the amount of



Fig 5. Circular dichroism spectra of Esc-(1-21) and [Aib⁸] at 20 µM measured in the presence of POPG/POCL (6:4 mol/mol) LUVs (500 µM). POPG: 1-palmitoyl-2oleoyl-sn-glycero-3-phosphoglycerol **POCL**: 1',3'-bis[1-palmitoyl-2-oleoyl-snglycero-3-phospho]-glycerol



Fig.6. Representative structure of [Aib⁸] peptide. Backbone is shown as ribbon and helical axes are shown as dotted lines.

Leu⁶ can be to observed followed by a 3_{10} helix from Ala⁷ to Lys⁹ and again by an α -helix from Lys¹⁰ to Ile^{16} ; C-terminal tail has also tendency to the helix but turns out to be more flexible. The structure can be described as distorted helix, bent on the Aib⁸ residue (Fig. 6).

An α -helix from Phe³

In the presence of liposomes mimicking the Gram-positive bacterial membrane, both CD spectra were characteristic of a helical structure. The intensity ratio between the two minima was greater than 1.0, indicating a helical conformation in its oligomeric state (Fig. 5).

Characterization of Mechanism of Action of [Aib⁸]

Cytoplasmic Membrane Perturbation

10000-

100-

50-

incubation.

Time (hours)

incubation times at 37°C. The percentage of non fresh

of intact peptide was detected even after 16h.

The percentage of intact peptide was ~90%, ~75%, and

~65% after 1, 3, and 4h of incubation, respectively.

Interestingly, after 5h treatment the nondegraded

amount of peptide was $\sim 40\%$ and the same percentage

Fig. 4 Stability of [Aib⁸] in 50% bovine at different

degraded peptide (%) after 1, 3, 4, 5, 16, and 24h

- 12.5 µM 🛨 6.25 μM
- To verify the membrane perturbation
 - mechanism of action of [Aib⁸] against | |

Membranolytic Mechanism by CF Leakage from POPG/POCL LUVs

The membranolytic mechanism of [Aib⁸] and the extent of peptide-induced

Structural Characterization of [Aib⁸]



Time (min)

Fig 7. Kinetics of cytoplasmic membrane permeabilization of S. aureus ATCC 25923. Sytox Green probe (1 μ M) was able to bind nucleic acids upon the impairment of the cytoplasmic membrane, resulting in an increase of fluorescence intensity. Control is given by microbial cells without peptide.

Gram-positive bacteria, the fluorescent probe Sytox Green was employed to carry out fluorescence studies on S. aureus ATCC 25923 during the first 30 minutes (Fig.7). [Aib⁸] induced a fast, and dosedependent membrane perturbation process. Already within the first minutes from its addition, the highest values of fluorescence intensity were recorded at the concentration range of 6.25-12.5 μM.



Fig 8. Effect of different concentrations of [Aib⁸] on the leakage of CF encapsulated into POPG/POCL (6:4, mol:mol) LUVs. LUVs were used at a final lipid concentration of 100 μ M.

membrane injury were also explored by using artificial large unilamellar vesicles (LUVs), mimicking the composition of the membrane of Gram-positive bacteria and loaded with fluorescent probe carboxyfluorescein (CF).

[Aib⁸] displayed a fast membraneperturbing activity with a total CF leakage within 5 min from its addition to the LUVs at 25 μ M (Fig. 8).

References

Luca, V. et al. Esculentin(1-21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa. Cell. Mol. Life Sci. 2013, 70, 2773-2786.

Loffredo, MR. Et al. Strategic Single-Residue Substitution in the Antimicrobial Peptide Esc(1-21) Confers Activity against Staphylococcus aureus, Including Drug-Resistant and Biofilm Phenotype. ACS Infect Dis. 2024 Jun 7. doi: 10.1021/acsinfecdis.4c00130.

Di Grazia, A. et al. D-Amino acids incorporation in the frog skin-derived peptide esculentin-1a(1–21)NH2 is beneficial for its multiple functions. Amino Acids 2015, 47, 2505–2519.

Conclusion

Our findings have contributed to explain how the incorporation of unconventional amino acids is a valid strategy to obtain promising candidates for the development of new anti-infective therapies.

Acknowledgements

This research was partially supported by EU funding within the NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT) to M.L.M and Fondazione Italiana per la Ricerca Cistica (Project FFC#4/2022) Delegazione FFC Ricerca di Roma e della Franciacorta e Val Camonica





